Effectiveness of aggressive prophylatic and preemptive therapies targeted against cytomegaloviral and Epstein-Barr viral disease after human intestinal transplantation

Transplant Proc. 2002 May;34(3):948-9. doi: 10.1016/s0041-1345(02)02710-0.

Authors

D G Farmer¹, S V McDiarmid, D Winston, H Yersiz, G Cortina, S Dry, A J Maxfield, B Vandenbogaart, M Correa, A Kroeber, S Geevarghese, R W Busuttil

Affiliation

¹ Department of Surgery, Dumont-UCLA Transplant Center, Los Angeles, California, USA.

PMID: 12034254
DOI: 10.1016/s0041-1345(02)02710-0

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antiviral Agents / therapeutic use*
Cytomegalovirus Infections / prevention & control*
Drug Administration Schedule
Drug Therapy, Combination
Epstein-Barr Virus Infections / prevention & control*
Ganciclovir / administration & dosage
Ganciclovir / therapeutic use*
Humans
Intestines / transplantation*
Retrospective Studies
Time Factors
Transplantation, Homologous

Substances

Antiviral Agents
Ganciclovir